Aeterna Zentaris Inc
F:ET8

Watchlist Manager
Aeterna Zentaris Inc Logo
Aeterna Zentaris Inc
F:ET8
Watchlist
Price: 1.59 EUR -1.24%
Market Cap: €7.7m

Net Margin

-193.6%
Current
Improving
by 76.3%
vs 3-y average of -269.9%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-193.6%
=
Net Income
$-14.9m
/
Revenue
$9.1m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-193.6%
=
Net Income
€-14.9m
/
Revenue
$9.1m

Peer Comparison

Country Company Market Cap Net
Margin
CA
Aeterna Zentaris Inc
F:ET8
7.7m EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
389.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.3B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
170.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
88.6B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.5B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.4B USD
Loading...

Market Distribution

Lower than 77% of companies in Canada
Percentile
23rd
Based on 4 909 companies
23rd percentile
-193.6%
Low
-9 940 586.9% — -85.9%
Typical Range
-85.9% — 5.5%
High
5.5% — 60 777.6%
Distribution Statistics
Canada
Min -9 940 586.9%
30th Percentile -85.9%
Median -7.8%
70th Percentile 5.5%
Max 60 777.6%

Aeterna Zentaris Inc
Glance View

Market Cap
7.7m EUR
Industry
Biotechnology

Aeterna Zentaris Inc. is a specialty biopharmaceutical company, which is engaged in commercializing and developing therapeutics and diagnostic tests. The Company's lead product, Macrilen (macimorelin), is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency (AGHD). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and has uses in both endocrinology and oncology indications. The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). It is also developing oral prophylactic bacterial vaccines against each of SARS-CoV-2, the virus that causes COVID-19, and Chlamydia Trachomatis. The Company focuses on the commercialization of macimorelin in Asia and the rest of the world.

ET8 Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-193.6%
=
Net Income
$-14.9m
/
Revenue
$9.1m
What is Aeterna Zentaris Inc's current Net Margin?

The current Net Margin for Aeterna Zentaris Inc is -193.6%, which is above its 3-year median of -269.9%.

How has Net Margin changed over time?

Over the last 3 years, Aeterna Zentaris Inc’s Net Margin has increased from -199.2% to -193.6%. During this period, it reached a low of -434% on Dec 31, 2022 and a high of -53.9% on Dec 31, 2023.

Back to Top